<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01935167</url>
  </required_header>
  <id_info>
    <org_study_id>DW1029M</org_study_id>
    <nct_id>NCT01935167</nct_id>
  </id_info>
  <brief_title>To Determine the Efficacy and Safety of DW1029M on Microalbuminuria in Patients With Diabetic Nephropathy</brief_title>
  <official_title>A Phase Ⅱ, Prospective, 24 Weeks, Double-blind, Placebo-controlled, Randomized, Multi-center Clinical Trial for the Evaluation of the Efficacy and Safety of DW1029M on Microalbuminuria in Patients With Diabetic Nephropathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dong Wha Pharmaceutical Co. Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dong Wha Pharmaceutical Co. Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase 2 clinical study to evaluate of the efficacy and safety of DW1029M on microalbuminuria
      in Patients With Diabetic Nephropathy
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Phase Ⅱ, prospective, 24 weeks, double-blind, placebo-controlled, randomized, multi-center
      clinical trial for the evaluation of the efficacy and safety of DW1029M on microalbuminuria
      in Patients With Diabetic Nephropathy
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2013</start_date>
  <completion_date type="Actual">February 2015</completion_date>
  <primary_completion_date type="Actual">August 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>log ACR</measure>
    <time_frame>24 weeks after 1st administration</time_frame>
    <description>logarithm of the Albumin Creatinine Ratio(ACR) after 24 weeks</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Log UAE</measure>
    <time_frame>24 weeks after 1st administration</time_frame>
    <description>Urinary Albumin Excretion(UAE) after 12 and 24 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>eGFR</measure>
    <time_frame>12 and 24 weeks after 1st administration</time_frame>
    <description>estimated Glomerular Filtration Rate(eGFR) after 12 and 24 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>log ACR</measure>
    <time_frame>12 weeks after 1st administration</time_frame>
    <description>logarithm of the Albumin Creatinine Ratio(ACR) after 12 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SCC</measure>
    <time_frame>12 and 24 weeks after 1st administration</time_frame>
    <description>Serum Creatinine Concentration(SCC) after 12 and 24 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cystatin C</measure>
    <time_frame>12 and 24 weeks after 1st administration</time_frame>
    <description>Cystatin C after 12 and 24 weeks</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">158</enrollment>
  <condition>Diabetic Nephropathy</condition>
  <arm_group>
    <arm_group_label>A Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DW1029M 600mg for 24 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DW1029M 1200mg for 24 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C Group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo for 24 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DW1029M 600mg</intervention_name>
    <description>DW1029M 150mg 2 tablets b.i.d</description>
    <arm_group_label>A Group</arm_group_label>
    <other_name>DW1029M 150mg 2 tablets</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DW1029M 1200mg</intervention_name>
    <description>DW1029M 300mg 2 tablets b.i.d</description>
    <arm_group_label>B Group</arm_group_label>
    <other_name>DW1029M 300mg 4 tablets</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo 2 tablets b.i.d.</description>
    <arm_group_label>C Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Has confirmed diabetic mellitus prior to 6years

          -  Has confirmed microalbuminuria 30 ~ 299㎍/㎎creatinine prior to 5months one time and
             microalbuminuria 30 ~ 299㎍/㎎creatinine during screening period

          -  Blood Pressure(BP) ≤ 150 / 90 mmHg

          -  estimated glomerular filtration rate(eGFR) ≥ 30 ml/min/1.73m2

          -  Hemoglobin A1c(HbA1c) ≤ 9%

          -  Low density lipoprotein(LDL-C) ≤ 130mg/dl

        Exclusion Criteria:

          -  kidney or liver disease as follows i.Serum Creatinine &gt; 2.0mg/dl ii.Alanine
             Aminotransferase(ALT) or Aspartate Aminotransferase(AST) &gt; 2 x Upper Limit Normal(ULN)
             iii.Total Bilirubin &gt; 2 x ULN

          -  Organic gastrointestinal disorder or Chronic gastroenterologic disorders prior to 6
             months as follows [NOTE] Active Crohn's disease, Active ulcerative colitis, Chronic
             peptic ulcer disease, etc.

          -  cardiovascular disease prior to 3 months as follows [NOTE] Unstable angina pectoris,
             Myocardial infarction, Coronary artery bypass surgery, Percutaneous Transluminal
             Coronary Angioplasty, transient ischemic attack, cerebrovascular accident etc.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MoonKyu Lee, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Samsung Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>DongWha Pharm</name>
      <address>
        <city>Seoul</city>
        <zip>100-130</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 30, 2013</study_first_submitted>
  <study_first_submitted_qc>September 3, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 4, 2013</study_first_posted>
  <last_update_submitted>February 16, 2017</last_update_submitted>
  <last_update_submitted_qc>February 16, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 17, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Microalbuminuria</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Diabetic Nephropathies</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

